MedTrace Logo

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2016-10-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.

Conditions

Interventions

DRUG

Canagliflozin

300 mg capsule, taken once daily, orally for 26 weeks.

DRUG

Phentermine

15 mg capsule, taken once daily, orally for 26 weeks.

DRUG

Matching Placebo to Canagliflozin

Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.

DRUG

Matching Placebo to Phentermine

Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02243202 on ClinicalTrials.gov